• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

在一名先前接受司库奇尤单抗治疗的银屑病患者使用比美吉珠单抗治疗期间出现的湿疹样皮疹。

Eczematous eruption during bimekizumab treatment in a psoriatic patient previously treated with secukinumab.

作者信息

Falco Gennaro Marco, Caldarola Giacomo, D'Amore Alessandra, Pinto Lorenzo Maria, De Simone Clara, Peris Ketty

机构信息

Dermatologia Dipartimento di Medicina e Chirurgia Traslazionale Università Cattolica del Sacro Cuore Rome Italy.

UOC di Dermatologia Dipartimento di Scienze Mediche e Chirurgiche Fondazione Policlinico Universitario A. Gemelli - IRCCS Rome Italy.

出版信息

Skin Health Dis. 2024 Aug 29;4(5):e371. doi: 10.1002/ski2.371. eCollection 2024 Oct.

DOI:10.1002/ski2.371
PMID:39355729
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11442047/
Abstract

Several eczematous eruptions have been described during treatment with anti-IL17A and anti-IL17 receptor drugs. In our case, however, the patient had been treated for 2 years with an IL-17A inhibitor without ever developing eczematous reactions, which occurred, however, shortly after starting therapy with bimekizumab, an IL-17A, F and A/F inhibitor.

摘要

在使用抗IL-17A和抗IL-17受体药物治疗期间，已有多种湿疹样皮疹的描述。然而，在我们的病例中，该患者用IL-17A抑制剂治疗了2年，从未出现过湿疹样反应，但在开始使用bimekizumab（一种IL-17A、F和A/F抑制剂）治疗后不久就出现了这种反应。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/065c/11442047/a2c21b2d7137/SKI2-4-e371-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/065c/11442047/9cec8b6137ac/SKI2-4-e371-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/065c/11442047/a2c21b2d7137/SKI2-4-e371-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/065c/11442047/9cec8b6137ac/SKI2-4-e371-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/065c/11442047/a2c21b2d7137/SKI2-4-e371-g003.jpg

相似文献

1
Eczematous eruption during bimekizumab treatment in a psoriatic patient previously treated with secukinumab.在一名先前接受司库奇尤单抗治疗的银屑病患者使用比美吉珠单抗治疗期间出现的湿疹样皮疹。
Skin Health Dis. 2024 Aug 29;4(5):e371. doi: 10.1002/ski2.371. eCollection 2024 Oct.
2
Clinical and histopathological characterization of eczematous eruptions occurring in course of anti IL-17 treatment: a case series and review of the literature.抗白细胞介素-17 治疗过程中出现的湿疹样发疹的临床和组织病理学特征：病例系列和文献复习。
Expert Opin Biol Ther. 2020 Jun;20(6):665-672. doi: 10.1080/14712598.2020.1727439. Epub 2020 Feb 17.
3
Bimekizumab treatment in patients with moderate to severe plaque psoriasis: a drug safety evaluation.中度至重度斑块状银屑病患者的比美吉珠单抗治疗：药物安全性评估
Expert Opin Drug Saf. 2023 Jan-Jun;22(5):355-362. doi: 10.1080/14740338.2023.2218086. Epub 2023 Jun 19.
4
Treatment of paradoxical eczematous eruption in psoriasis treated with secukinumab: A case report.司库奇尤单抗治疗银屑病后出现矛盾性湿疹样发疹的治疗：一例报告。
Medicine (Baltimore). 2023 Feb 10;102(6):e32844. doi: 10.1097/MD.0000000000032844.
5
Bimekizumab: a dual IL-17A and IL-17F inhibitor for the treatment of psoriasis and psoriatic arthritis.比美替尼：一种用于治疗银屑病和银屑病关节炎的双重 IL-17A 和 IL-17F 抑制剂。
Expert Rev Clin Immunol. 2021 Oct;17(10):1073-1081. doi: 10.1080/1744666X.2021.1967748. Epub 2021 Aug 20.
6
The Clinical Significance of Simultaneous IL-17A and IL-17F Blockade in Psoriasis Non-Responding to Anti-IL17A Therapy.白细胞介素-17A和白细胞介素-17F联合阻断在对抗白细胞介素-17A治疗无反应的银屑病中的临床意义
J Clin Med. 2022 Dec 21;12(1):35. doi: 10.3390/jcm12010035.
7
Bimekizumab: the new drug in the biologics armamentarium for psoriasis.比美吉珠单抗：银屑病生物制剂库中的新药。
Drugs Context. 2021 Jun 8;10. doi: 10.7573/dic.2021-4-1. eCollection 2021.
8
Matching-Adjusted Indirect Comparison of the 52-Week Efficacy of Bimekizumab Versus Secukinumab and Ixekizumab for the Treatment of Radiographic Axial Spondyloarthritis.对比昔美克珠单抗与司库奇尤单抗及依奇珠单抗治疗放射学中轴型脊柱关节炎52周疗效的匹配调整间接比较
Rheumatol Ther. 2024 Aug;11(4):1023-1041. doi: 10.1007/s40744-024-00684-z. Epub 2024 Jun 25.
9
Bimekizumab: A Review in Psoriatic Arthritis.比美吉珠单抗：治疗银屑病关节炎的研究进展。
Drugs. 2024 May;84(5):587-598. doi: 10.1007/s40265-024-02026-3. Epub 2024 May 4.
10
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.慢性斑块状银屑病的全身药理学治疗：一项网状Meta分析。
Cochrane Database Syst Rev. 2020 Jan 9;1(1):CD011535. doi: 10.1002/14651858.CD011535.pub3.

引用本文的文献

1
Long-Term Effectiveness and Safety of Bimekizumab in Patients with Moderate to Severe Hidradenitis Suppurativa Under Real Clinical Practice Conditions: The Importance of Combined Treatment in Hurley III Patients and Potential Factors Associated with Complete Response.在真实临床实践条件下，比美吉珠单抗治疗中度至重度化脓性汗腺炎患者的长期有效性和安全性：对Hurley III期患者联合治疗的重要性及与完全缓解相关的潜在因素
Dermatol Ther (Heidelb). 2025 Aug 27. doi: 10.1007/s13555-025-01521-z.

本文引用的文献

1
Eczematous drug eruption in patients with psoriasis under anti-interleukin-17A: does interleukin-22 play a key role?接受抗白细胞介素-17A治疗的银屑病患者出现的药疹样药物性皮疹：白细胞介素-22起关键作用吗？
Clin Exp Dermatol. 2022 May;47(5):918-925. doi: 10.1111/ced.15052. Epub 2022 Feb 9.
2
Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial.比美吉珠单抗与乌司奴单抗治疗中度至重度斑块型银屑病（BE VIVID）：一项为期 52 周、多中心、双盲、活性对照和安慰剂对照的 3 期临床试验的疗效和安全性。
Lancet. 2021 Feb 6;397(10273):487-498. doi: 10.1016/S0140-6736(21)00125-2.
3
Mixed profile of cytokines in paradoxical eczematous eruptions associated with anti-IL-17 therapy.
与抗IL-17治疗相关的矛盾性湿疹样皮疹中细胞因子的混合谱。
J Allergy Clin Immunol Pract. 2020 Nov-Dec;8(10):3619-3621.e1. doi: 10.1016/j.jaip.2020.06.064. Epub 2020 Jul 18.
4
Clinical and histopathological characterization of eczematous eruptions occurring in course of anti IL-17 treatment: a case series and review of the literature.抗白细胞介素-17 治疗过程中出现的湿疹样发疹的临床和组织病理学特征：病例系列和文献复习。
Expert Opin Biol Ther. 2020 Jun;20(6):665-672. doi: 10.1080/14712598.2020.1727439. Epub 2020 Feb 17.
5
Phenotypic switch to eczema in patients receiving biologics for plaque psoriasis: a systematic review.接受生物制剂治疗斑块状银屑病患者出现湿疹样表型转换：一项系统评价
J Eur Acad Dermatol Venereol. 2020 Jul;34(7):1440-1448. doi: 10.1111/jdv.16246. Epub 2020 Feb 27.
6
IL-17C amplifies epithelial inflammation in human psoriasis and atopic eczema.IL-17C 增强人类银屑病和特应性皮炎中的上皮炎症。
J Eur Acad Dermatol Venereol. 2020 Apr;34(4):800-809. doi: 10.1111/jdv.16126. Epub 2020 Jan 19.
7
Interleukin-17C promotes Th17 cell responses and autoimmune disease via interleukin-17 receptor E.白细胞介素-17C 通过白细胞介素-17 受体 E 促进 Th17 细胞应答和自身免疫性疾病。
Immunity. 2011 Oct 28;35(4):611-21. doi: 10.1016/j.immuni.2011.09.010. Epub 2011 Oct 6.